Amedisys (NASDAQ:AMED) Rating Reiterated by Oppenheimer

Amedisys (NASDAQ:AMEDGet Rating)‘s stock had its “outperform” rating reaffirmed by analysts at Oppenheimer in a research report issued to clients and investors on Friday. They currently have a $200.00 price target on the health services provider’s stock. Oppenheimer’s target price points to a potential upside of 51.64% from the stock’s current price.

A number of other equities research analysts also recently issued reports on the stock. Royal Bank of Canada reduced their price objective on shares of Amedisys from $221.00 to $199.00 and set an “outperform” rating on the stock in a research note on Friday, February 25th. Benchmark reduced their price objective on shares of Amedisys from $200.00 to $175.00 and set a “buy” rating on the stock in a research note on Thursday, February 24th. Raymond James reduced their price objective on shares of Amedisys from $200.00 to $180.00 in a research note on Friday. Credit Suisse Group reduced their price objective on shares of Amedisys from $200.00 to $195.00 and set an “outperform” rating on the stock in a research note on Friday, February 25th. Finally, Zacks Investment Research upgraded shares of Amedisys from a “sell” rating to a “hold” rating and set a $180.00 price objective on the stock in a research note on Tuesday, April 5th. Seven analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $191.06.

AMED stock opened at $131.89 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.95 and a current ratio of 0.95. The company’s 50-day simple moving average is $156.26 and its 200 day simple moving average is $154.20. Amedisys has a 52 week low of $122.12 and a 52 week high of $292.97. The company has a market capitalization of $4.29 billion, a PE ratio of 20.80, a price-to-earnings-growth ratio of 2.46 and a beta of 0.72.

Amedisys (NASDAQ:AMEDGet Rating) last released its quarterly earnings results on Wednesday, April 27th. The health services provider reported $1.23 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.12 by $0.11. Amedisys had a net margin of 9.44% and a return on equity of 21.84%. During the same period in the prior year, the firm earned $1.54 EPS. On average, analysts forecast that Amedisys will post 5.31 EPS for the current year.

In related news, insider David L. Kemmerly sold 2,500 shares of the firm’s stock in a transaction that occurred on Tuesday, March 29th. The shares were sold at an average price of $177.31, for a total value of $443,275.00. Following the completion of the transaction, the insider now owns 16,336 shares in the company, valued at approximately $2,896,536.16. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 1.80% of the stock is owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the business. Covestor Ltd bought a new position in Amedisys during the 4th quarter worth approximately $28,000. Harel Insurance Investments & Financial Services Ltd. raised its holdings in Amedisys by 55.3% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 233 shares of the health services provider’s stock worth $38,000 after purchasing an additional 83 shares during the last quarter. Allworth Financial LP bought a new position in Amedisys during the 1st quarter worth approximately $38,000. Zullo Investment Group Inc. bought a new position in Amedisys during the 4th quarter worth approximately $40,000. Finally, Confluence Wealth Services Inc. bought a new position in Amedisys during the 4th quarter worth approximately $42,000. Hedge funds and other institutional investors own 92.18% of the company’s stock.

About Amedisys (Get Rating)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Featured Articles

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.